
The U.S. Food and Drug Administration on Monday approved a second nasal spray for reversing an opioid overdose. To be sold as Opvee, the spray contains the medication nalmefene hydrochloride and will be available to Americans aged 12 and older with a prescription, the FDA said. “The agency continues to advance the FDA Overdose Prevention… read on > read on >